1Steinhubl SR, Berger PB, Mann JT Ⅲ, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention : a randomized controlled trial [ J ]. JAMA,2002,288:2411 - 2420.
2Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel[ J]. Am J Cardiol,2003,91 : 1123 - 1125.
3Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals [ J ]. J Am Coll Cardiol, 2005,45:246 - 251.
4Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo.P2Y12 receptor antagonist activity[J]. Semin Thromb Hemost,2005,31:184 - 194.
5Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet fimetion: magnitudc, of platelet inhibition is related to active metabolite formation [ J]. Am Heart J,2007,153:66. e9 - 16.
6Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose elopidogrel[ J]. J Cardiovase Pharmacol, 2007, 50:555 - 562.
7Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status [ J ]. Am J Cardiol,2007 ,100 :331 - 336.
8Asai F, Jakubowski JA, Naganuma H, et al. Platelet inhibitory activity and pharmacokinctics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor:a single ascending dose study in healthy humans[ J]. Platelets, 2006,17:209 - 217.
9Matsushima N, Jakubowski JA, Asai F, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel ( CS-747 ) a novel thienopyridine P2Y12 inhibitor:a muhiple-dose study in healthy humans[ J]. Platelets,2006,17:218 - 226.
10Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel ( CS-747 ), a novel thienopyridine P2Y 12 inhibitor, compared with clopidogrel in healthy humans[ J]. Br J Clin Pharmacol,2007,63:421 -430.
